Evidence map›Paper›PMID 25225603›Full record

ReviewWorld journal of biological chemistry2014

Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants.

Sugreev Verma, Kousik Kesh, Nilanjan Ganguly, Sayantan Jana, Snehasikta Swarnakar

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Tumor TargetingMicroRNA (Shariqah, United Arab Emirates) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Knockdown of MON1B Exerts Anti-Tumor Effects in Colon Cancer In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  18. Article
  19. The constitutive protease release by primary human acute myeloid leukemia cells.Journal of cancer research and clinical oncology · 2017
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sugreev VermaSugreev Verma, Kousik Kesh, Nilanjan Ganguly, Sayantan Jana, Snehasikta Swarnakar, Drug Development Diagnostic and Biotechnology Division, CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata 700032, India.
Kousik KeshSugreev Verma, Kousik Kesh, Nilanjan Ganguly, Sayantan Jana, Snehasikta Swarnakar, Drug Development Diagnostic and Biotechnology Division, CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata 700032, India.
Nilanjan GangulySugreev Verma, Kousik Kesh, Nilanjan Ganguly, Sayantan Jana, Snehasikta Swarnakar, Drug Development Diagnostic and Biotechnology Division, CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata 700032, India.
Sayantan JanaSugreev Verma, Kousik Kesh, Nilanjan Ganguly, Sayantan Jana, Snehasikta Swarnakar, Drug Development Diagnostic and Biotechnology Division, CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata 700032, India.
Snehasikta SwarnakarSugreev Verma, Kousik Kesh, Nilanjan Ganguly, Sayantan Jana, Snehasikta Swarnakar, Drug Development Diagnostic and Biotechnology Division, CSIR-Indian Institute of Chemical Biology, Jadavpur, Kolkata 700032, India.
Indian Institute of Chemical Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The process of carcinogenesis is tightly regulated by antioxidant enzymes and matrix degrading enzymes, namely, matrix metalloproteinases (MMPs). Degradation of extracellular matrix (ECM) proteins like collagen, proteoglycan, laminin, elastin and fibronectin is considered to be the prerequisite for tumor invasion and metastasis. MMPs can degrade essentially all of the ECM components and, most MMPs also substantially contribute to angiogenesis, differentiation, proliferation and apoptosis. Hence, MMPs are important regulators of tumor growth both at the primary site and in distant metastases; thus the enzymes are considered as important targets for cancer therapy. The implications of MMPs in cancers are no longer mysterious; however, the mechanism of action is yet to be explained. Herein, our major interest is to clarify how MMPs are tied up with gastrointestinal cancers. Gastrointestinal cancer is a variety of cancer types, including the cancers of gastrointestinal tract and organs, i.e., esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The activity of MMPs is regulated by its endogenous inhibitor tissue inhibitor of metalloproteinase (TIMP) which bind MMPs with a 1:1 stoichiometry. In addition, RECK (reversion including cysteine-rich protein with kazal motifs) is a membrane bound glycoprotein that inhibits MMP-2, -9 and -14. Moreover, α2-macroglobulin mediates the uptake of several MMPs thereby inhibit their activity. Cancerous conditions increase intrinsic reactive oxygen species (ROS) through mitochondrial dysfunction leading to altered protease/anti-protease balance. ROS, an index of oxidative stress is also involved in tumorigenesis by activation of different MAP kinase pathways including MMP induction. Oxidative stress is involved in cancer by changing the activity and expression of regulatory proteins especially MMPs. Epidemiological studies have shown that high intake of fruits that rich in antioxidants is associated with a lower cancer incidence. Evidence indicates that some antioxidants inhibit the growth of malignant cells by inducing apoptosis and inhibiting the activity of MMPs. This review is discussed in six subchapters, as follows.

Indexed as

AntioxidantsGastrointestinal cancerMatrix metalloproteinaseReactive oxygen speciesTissue inhibitor of matrix metalloproteinases

Identifiers

PMID25225603
PMCPMC4160529
OpenAlexW2069542592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.